secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086103
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY
---------------------------------------------------------------------

- Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.
- Non-GAAP adjusted diluted EPS $1.12 (down 15% YoY); GAAP diluted EPS $0.75 (down 21%).
- Women's Health +3%, Biosimilars +22% driven by Hadlima launch; Established Brands -1% ex-FX.
- FY2024 revenue guidance narrowed to $6.25-6.45B; Adjusted EBITDA margin reaffirmed 31-33%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/0001104659-24-086103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924086103/tm2420930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer